Another day, another clinical trial to conquer COVID-19. And this covers a lot of ground. According to the National Institutes of Health, a phase 3 clinical trial combining the antiviral remdesivir with the hyperimmune intravenous anti-coronavirus hyperimmune immunoglobulin is being conducted at 59 locations in 18 countries, including the United States.
Remdisivir is an investigational antiviral drug that has been tested for the treatment of hepatitis, Ebola and SARS, among other things.
The National Institute for Allergies and Infectious Diseases sponsors and funds the study, which is known as inpatient treatment with anti-coronavirus immunoglobulin [ITAC].
The theory behind the treatment, according to the NIH, is that people infected with COVID-19 who receive the immunoglobulin at the onset of the disease may make their own antibodies to the virus and fight it off at the onset of symptoms to avoid serious complications.
"Finding safe and effective treatments for COVID-19 is absolutely critical," said NIAID Director Anthony S. Fauci, MD, in the press release. "The ITAC study is investigating whether adding anti-coronavirus HIVIG to a remdesivir regimen can give the immune system the boost it needs to suppress SARS-CoV-2 early in the course of the disease and nip the infection in the bud. "
The study will be carried out at locations in Africa, Asia, Europe, North America and South America.
The researchers hope to enroll 500 adult patients who have been hospitalized with COVID-19 and have had symptoms for 12 days or less. You must not have any other serious illness such as organ failure or dysfunction.
Study participants will be monitored for their response to the treatments, including side effects and how long it takes for their symptoms to go away. The researchers will follow the participants for 28 days.
For more information on the ITAC study, visit ClinicalTrials.gov. Search for the study ID NCT04546581.